CLOs on the Move

Motif Neurotech

www.motifneuro.tech

 
Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

corpak medsystems

corpak medsystems is a Buffalo Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Invictus Medical

Founded in 2011, Invictus Medical is a privately owned Delaware “C” Corporation with headquarters in San Antonio, Texas. Currently, we are in the latter stages of developing our award-winning cranial support technology into our first product for commercialization. To secure early healthy development in newborns by providing innovative products, services, and solutions to the healthcare professional and consumer markets. Invictus Medical is committed to providing safe and effective medical products and high levels of service to the healthcare and consumer markets.

Swift Optics

Swift Optics is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Acmedent Corporation

Acmedent Corporation is a Concord, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

www.biosig.com

BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.